Ceryvyn TherapeuticsASX:CYV -7.69% EV-to-EBIT is -0.27 as of Jul. 11, 2026. The stock has 3 warning signs investors should review. Among 366 Biotechnology companies, Ceryvyn Therapeutics ranks worse than 273223.77% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Ceryvyn Therapeutics's Enterprise Value for the quarter that ended in Jun. 2025 was A$664.68 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ceryvyn Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was A$-194.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ceryvyn Therapeutics EV-to-EBIT Related Terms
Ceryvyn Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Ceryvyn Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CYV vs VRTX, REGN, ALNY: EV-to-EBIT Comparison
For the Biotechnology subindustry, Ceryvyn Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ceryvyn Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ceryvyn Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Ceryvyn Therapeutics's EV-to-EBIT falls into.
Ceryvyn Therapeutics's current Enterprise Value is A$53.17 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ceryvyn Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was A$-194.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ceryvyn Therapeutics (ASX:CYV) has a EV-to-EBIT of -0.27 as of Jul. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ceryvyn Therapeutics and its competitors. According to the industry distribution chart, Ceryvyn Therapeutics ranks #999999 out of 366 companies in the Biotechnology industry.
Is Ceryvyn Therapeutics' EV-to-EBIT too high?
Ceryvyn Therapeutics' current EV-to-EBIT is -0.27. Based on the distribution chart, Ceryvyn Therapeutics ranks #999999 out of 366 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Ceryvyn Therapeutics' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ceryvyn Therapeutics ranks #999999 out of 366 companies for EV-to-EBIT. This places Ceryvyn Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 15.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.02, based on 366 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ceryvyn Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ceryvyn Therapeutics's current EV-to-EBIT is -0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current EV-to-EBIT of -0.27. The current EV-to-EBIT is -0.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Ceryvyn Therapeutics (ASX:CYV), the current EV-to-EBIT is -0.27 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYV has been successfully added to your 